Epilepsy

The treatment for Dravet syndrome showed 63.9% average reduction in monthly seizures, as well as a seizure-free period at 20.5 days.

APTIOM provides an important new treatment option for partial-onset seizures in pediatric patients ages 4 and up for adjunctive and monotherapy use.

BRIVIACT and Aptiom were both previously approved for more particular indications in partial-onset seizure treatment.

The seizure-causing condition now inflicts at least 3.4 million US patients, according to the CDC.

The drug has been approved in 55 countries and used to treat 100,000 patients.

VNS Therapy was previously approved as a drug-resistant epilepsy treatment in seizure patients ages 12 and older.

AT AAN 2017, Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine spoke with MD Magazine about the latest advancements in epilepsy research.

Follow-up data from TOPIC, CARE-MS II trials positive for the two MS drugs.

“Unlikely to have clinically relevant interactions with any commonly prescribed AEDs.”

“When we make recommendations, we don’t just use the evidence from the studies.”

Risk of death in epilepsy "almost the elephant in the room,” according to Donner.

Cannabidiol may cut the number of seizures for some patients who have epilepsy.

Multiple sclerosis can lead to seizures. Researchers found the mechanism.

Northwell Health is testing laser ablation for temporal lobe epilepsy.